$IRD

SCHACHLE JOSEPH K sold $14K of IRD

SCHACHLE JOSEPH K (Chief Operating Officer) sold 4,644 shares of Opus Genetics, Inc. (IRD) at $2.94 on 2026-07-23.

Original reporting
SEC EDGAR · SCHACHLE JOSEPH K
Published Jul 27, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRD
Neutral
medium confidence
Mentioned
$IRD
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRDNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment signal, but this disclosure alone does not provide new business or financial guidance.

02

Market read

A COO open-market sale at $2.94/share is newly disclosed, offering a modest sentiment datapoint rather than a catalyst.

03

What to watch

The filing does not disclose motivations, and the article provides only one sale transaction without context on prior insider activity or total holdings changes over time.

Relevance 3/10Novelty 4/10Timing: new Form 4 disclosure filed after-hours on 2026-07-27

Background

The article is a primary-source SEC Form 4 insider transaction for Opus Genetics, Inc.

Company-level read

Ticker impact

$IRDNeutralMedium confidence
Context

Opus Genetics COO Joseph K. Schach sold 4,644 shares in an open-market transaction at $2.94/share, per Form 4 filed July 27.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

Form 4 provides a fresh datapoint on insider selling, but insider sales are common and the article lacks any accompanying operational or guidance catalyst.

Market effects

No sector-level read-across; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply bearish intent; sales can be driven by diversification or tax planning.

Key entities

  • Opus Genetics, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • SCHACHLE JOSEPH K

    Chief Operating Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRDMed

Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics (Nasdaq: IRD) reported Q2 2026 results for the quarter ended June 30, 2026. Cash was $88.8 million, expected to fund operations into 2029. Revenue fell to $0.8 million from $2.9 million. R&D rose to $11.2 million. Net loss was $8.1 million. The company also updated clinical timelines for OPGx-BEST1, OPGx-LCA5, and other programs.

$IRDMed

Opus Genetics, Inc.: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 trial (BIRD-1) for BEST1-associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, with Month 3 data expected in the second week of September 2026. The company plans to present at EURETINA in October 2026 and submit Month 3 results to the FDA for next steps.